Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Mar 19, 2022
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age over 18
- • Patients consented to participate
- • Pathologically diagnosed ovarian cancer FIGO stage IC-IVB
- • ECOG 0-2
- • Patients with an expected survival of 3 months or more
- Exclusion Criteria:
- • History of paclitaxel or carboplatin hypersensitivity
- • Inadequate bone marrow function (Neutrophil\<1500/mm3, Platelet \<100,000/mm3)
- • Pregnancy or breast-feeding state
- • Metachronous or synchronous malignancy
- • Galactose intolerance, Lapp Lactase deficiency, or glucose-galactose malabsorption patients with genetic problems
- • Other patients who were judged difficult to be included in this investigation by the investigator in charge
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Suwon, , Korea, Republic Of
Patients applied
Trial Officials
Hee Seung Kim
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials